Meet Daniela Drago, Ph.D. and Helen Kim, regulatory affairs experts at NDA Partners and Umoja Biopharma, respectively, and tune in for the opening segment of our recent live panel discussion on risk-proofing your IND submission. In this segment of the Bioprocess Online Live event IND Success: Navigate Through The Regulatory Gray, Drago and Kim address two of the most common IND mistakes biopharmas make—neglecting the value of a pre-IND meeting, and underestimating the time and energy required of successful submissions.

Check out the full presentation here [ Ссылка ]

свернуть